GSK plc (GLAXF)
OTCMKTS
· Delayed Price · Currency is USD
19.25
+0.15 (0.76%)
Aug 14, 2025, 12:18 PM EDT
GSK plc Revenue
GSK plc had revenue of 7.99B GBP in the quarter ending June 30, 2025, with 1.29% growth. This brings the company's revenue in the last twelve months to 31.63B, up 0.59% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.63B GBP
Revenue Growth
+0.59%
P/S Ratio
1.80
Revenue / Employee
460.90K GBP
Employees
68,629
Market Cap
77.94B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 84.04M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
BioStem Technologies | 332.45M |
GSK plc News
- 5 days ago - GSK's antibiotic drug gepotidacin gets priority review by FDA - Reuters
- 6 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK - GlobeNewsWire
- 7 days ago - Drugmaker GSK lands £372m in Covid jab pact - This is Money
- 7 days ago - GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - Seeking Alpha
- 7 days ago - GSK to be paid up to £370 million after patent row settles in US - Evening Standard
- 8 days ago - GSK to Receive $370 Million in U.S. Patent Litigation Settlement - WSJ
- 10 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK - GlobeNewsWire
- 14 days ago - Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges - WSJ